List view / Grid view




Apitope’s Phase II multiple sclerosis trial a success

22 February 2017 | By Niamh Marriott, Digital Editor

Apitope, the drug discovery and development company focused on treating the underlying cause of autoimmune diseases, announces positive results from the Phase IIa clinical study of its lead product candidate, ATX-MS-1467, for the treatment of patients with multiple sclerosis. The Phase IIa, open-label, one arm study evaluated the effects of…